Abstract Seventy-seven patients with proximal femoral tumours underwent limb salvage surgery with custom mega prostheses between July 1989 and January 2002. We describe 44 cases with a mean follow-up of 57.8 months. Forty-one patients presented with malignant neoplasms of which 11 were malignant giant cell tumours, eight were chondrosarcoma and five were metastases. Wide margins were achieved for all malignant tumours, and marginal resection was done for all benign and metastatic lesions. Six patients died of disease and two were lost to follow-up. Mechanical complications were observed in six cases, fracture being the most common. Oncological complications occurred in five patients. Functional activity was satisfactory in 79% of patients.
Introduction
Limb-salvage surgery for benign and malignant tumours has reached unforeseen strides in recent times. With advances in cancer chemotherapy and better investigational backup, salvaging limbs that otherwise would have been amputated has evolved into a continuing and accepted concept of the new millennium. This requires a multidisciplinary approach involving various surgical fields like vascular and plastic specialities.
Resection of tumours and reconstruction of the proximal femur with various methodologies like arthrodesis with autograft or allograft; rotation plasty; bone transport techniques such as that of Ilizarov; and arthroplasty using allografts, allograft-prosthesis composites and endoprosthesis, have been in vogue [8] .
Compared with various reconstructive methods available, prosthetic replacement offers several advantages, such as early stability, mobilisation and weightbearing [11, 12, 13] . Adjuvant treatment with chemotherapy and radiotherapy for providing pre-operative downstaging and control of micro-metastasis improve the oncological outcome [2, 10] .
Materials and methods
During the period July 1989 to January 2002, 77 patients with tumours of the proximal femur underwent limb salvage surgery with custom mega-prosthesis in various institutions. Patients treated after August 2000 were excluded from the series.
We describe 44 patients of whom six have died of disease and two were lost to follow-up. We present the oncological results and functional outcome of prosthetic replacement in those 44 patients followed-up for a minimum of 24 months. We also evaluated the rate of prosthetic and limb survival and overall survival, and early and late complications. Mean follow-up period was 57 months. Male/female ratio was 1:1 with an age range of 14-66 (mean 34.5) years.
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Diagnosis and tumour grade
We encountered 41 malignant tumours. Giant cell tumours formed 11 cases; eight were cases of chondrosarcoma followed in number by metastases and osteosarcoma. Surgical staging was done according to Enneking's staging system [3] for benign and malignant tumours based on radiological and histopathological evaluation. The majority of the patients with malignant tumour presented as stages IB and IIB. Computerised tomography helped evaluate the tumour extent in 17 patients. Technetium-99m bone scan was done in 13 patients to assess bone metastasis. Open biopsy was done in 23 patients. Lesion length ranged from 20 mm to 270 mm with an average of 108 mm. Soft-tissue encroachment was observed in 11 cases, and 22 patients presented with a pathological fracture. Table 1 summarises histopathological diagnoses, surgical stages encountered, pre-operative and post-operative chemotherapy, pre-operative radiotherapy, follow-up period, and functional and oncological outcomes with complications. Pre-operative chemotherapy was given to 12 patients with malignant tumours. Pre-operative irradiation was given to six patients. Fifteen patients presented with a history of previous surgery in the form of excision, curettage and bone grafting done especially for benign tumours. Twelve patients received post-operative chemotherapy.
Resection
Surgical margins were wide in 17 patients and marginal in 25. In a case of non-Hodgkin's lymphoma the margin was contaminated. One patient presented with chondromyxoid fibroma after excision. The most frequent length of resection was between 100 and 150 mm.
Reconstruction
Prostheses used were indigenously manufactured, customised to each patient with either stainless steel (37 patients) or titanium alloy. Vitallium alloy was used in a total hip prosthesis after resection of an osteosarcoma. Required prosthesis dimensions were estimated using X-rays in all patients. Total hip replacement prosthesis was used in 27 patients and proximal femoral prosthesis in the remaining patients (Fig. 1) .
Results
Patients were evaluated every 3 months during the first year and 6 monthly thereafter with physical examination and plain radiography.
Complications
Three patients had intra-operative complications, which were manageable. Three patients had post-operative deep-wound infection, which was managed conservatively with antibiotics in one patient, the prosthesis was removed in one and the limb removed in the other. Six patients had mechanical complications, two in the form of reducible dislocations with satisfactory functional results. Fractures were observed in three patients among whom one patient had a revision giving an excellent result, one was lost to follow-up and the other died of disease. One patient had a satisfactory functional result despite aseptic loosening at the bone/cement interface. Five patients showed evidence of oncological complications that took the form of lung metastases in two cases of Ewing's sarcoma and in one case of osteosarcoma; all three succumbed to the disease. Local recurrence occurred in two cases of chondrosarcoma.
Functional outcome
Functional outcome was estimated using Enneking's evaluation criteria [4] , an assessment that evaluates pain, functional limitation, walking distance, use of support, gait and emotional acceptance as parameters. At their latest follow-up, 27 patients had excellent functional outcome, eight good, three fair and four poor. Two patients with metastatic lesions were lost to follow-up at 120 and 62 months respectively. Fig. 1 a Pre-operative radiograph of a case of chondrosarcoma of the proximal femur. b Post-operative radiograph after resection and custom mega-prosthetic replacement -1-year follow-up
Oncological outcome
There was no evidence of disease in 34 patients, two were alive with disease and six had died of disease (Table 2).
Survivorship analysis
The survival analysis was done using the Kaplan-Meier survivorship method, using the following parameters:
1. Patient survivorship with death as the end point 2. Limb survivorship with amputation as the end point 3. Prostheses survivorship with mechanical failure and revision as the end point.
Prosthesis 5-year survival percentage was 97.2%; limb survival rate was 94.5% and patient survival rate was 87.2% (Fig. 2) .
Discussion
This series represents custom mega prosthesis as a reliable method of reconstruction following resections of malignant tumours of the proximal femur. Major advantages of this method are early functional recovery, a relatively low complication rate and a high level of emotional acceptance. In contrast with most series [6, 7] , fractures outnumbered dislocations after proximal and total femoral resection and reconstruction. Local recurrence, as a marker of local tumour control, was observed only in two cases, denoting the oncological adequacy of the resections. Both of these patients had extra-compartmental chondrosarcoma; no case of osteosarcoma had a local recurrence. This overall recurrence rate fares superior to that reported by a similar series by Kabukcuoglu et al [9] who report a rate as high as 28%. This rate reiterates the fact that generous excision margins are needed in such tumours.
In our series, infections were met with in three cases only, which is lower when compared to reconstruction procedures like osteoarticular allografts, allograft prosthesis composites and allograft-arthrodesis after tumour resections, infection, the rate in those instances being 11% [1, 5] . Also, these methods have problems of nonunion (3.7-15%), problems that did not arise with our endoprostheses. In the same series, allograft fractures were 19%. In our series, only three cases (6.8%) of periprosthetic fractures were encountered, indicating that, with an equivalent successful outcome of 80%, the morbidity associated with endoprosthetic replacement is remarkably low.
Patients with osteosarcoma performed considerably worse than those with chondrosarcoma as regards oncological outcome ( Table 2 ). The number of survivors was the least (1/3) with Ewing's sarcoma, understandably as these patients presented to us with higher surgical stages.
Breakage of prosthesis occurred in none of our patients, results that fared better than the reports that quote as high as 1-4% [14, 15] . This was probably due to improving implant design and metallurgy. Treating malignant tumours of the proximal femur with its unique problems has remained one of the complex areas of management in orthopaedic oncology. As patients present to us in different surgical stages, contemplating limb salvage with the support of chemotherapy and endoprosthetic reconstruction needs a meticulous patient selection, an individualised approach to the tumour type and consideration of the likely functional recovery, making it almost impossible to decide which modality of reconstruction could offer the best overall results. Our indigenously manufactured custom mega prostheses have proved to serve as a better limb-salvage procedure as regards local recurrence rate and morbidity, besides satisfactory oncological and functional outcomes when compared with the various modalities of reconstruction.
